EXAS Stock Surges 19% Amid Insider Trading and Analyst Optimism

In-Depth Analysis

Exact Sciences ($EXAS) has experienced a significant stock surge, prompting a closer look at the underlying factors driving this movement.

**Insider Trading Activity:** Over the past six months, insiders have predominantly sold shares. Key transactions include:

Katherine S Zanotti sold 15,207 shares for approximately $950,612.
Brian Baranick sold 2,858 shares for roughly $200,288.
James Herriott sold 3,000 shares for about $195,120.
James Edward Doyle sold 3,485 shares for approximately $182,399.

Track insider transactions on Quiver Quantitative's insider trading dashboard?ref=yanuki.com.

**Hedge Fund Activity:** Institutional investors display varied strategies:

FMR LLC decreased its holdings by 8,241,935 shares (-30.6%).
WELLINGTON MANAGEMENT GROUP LLP reduced its stake by 6,677,809 shares (-55.6%).
CITADEL ADVISORS LLC increased its position by 3,506,084 shares (+805.1%).
CANADA PENSION PLAN INVESTMENT BOARD added 2,500,056 shares (+2439.1%).
ARK INVESTMENT MANAGEMENT LLC increased its holdings by 2,186,132 shares (+6072588.9%).

Monitor hedge funds' portfolios on Quiver Quantitative's institutional holdings dashboard?ref=yanuki.com.

**Government Contracts:** $EXAS has received $592,152 in government contract award payments over the last year. Key awards include:

TESTING SERVICES FOR PATIENT CARE: $323,800
ONCOTYPE CANCER TESTING - OY 5 POP: $124,588
ONCOTYPE GENETIC TESTING SERVICES: $114,305

**Analyst Ratings & Price Targets:** Wall Street analysts are largely optimistic:

Piper Sandler: Overweight rating, target price of $80.0 (11/11/2025)
Wells Fargo: target price of $85.0 (11/05/2025)
Baird: Outperform rating, target price of $88.0 (11/04/2025)

The median price target from 13 analysts is $80.0.

Track data on Quiver Quantitative?ref=yanuki.com.

Read source article

FAQ

What is driving the EXAS stock surge?

The surge is influenced by insider trading activity, hedge fund movements, positive analyst ratings, and optimistic price targets.

Are insiders buying or selling EXAS stock?

Over the last six months, insiders have primarily been selling shares.

What are analysts' price targets for EXAS?

The median price target from 13 analysts is $80.0, with targets ranging from $75 to $88.

Takeaways

Monitor insider trading activity for potential signals about company performance.
Keep an eye on hedge fund movements to gauge institutional sentiment.
Consider analyst ratings and price targets as part of your investment decision-making process.
Be aware of government contracts, which can provide a stable revenue stream.

Discussion

Do you think this trend will last? Let us know!

Share this article with others who need to stay ahead of this trend!

Sources

$EXAS stock is up 19% today. Here's what we see in our data. Abbott is weighing takeover of Exact Sciences, Bloomberg News reports Abbott Nears Deal for Cancer Test Maker Exact Sciences

Disclaimer

This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.

All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.

This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.

Always do your own research (DYOR) before making any decisions based on the information presented.